IMPACT BIOMEDICAL INC. (IBO) Form 10-Q — Aug 7, 2026
Impact BioMedical posted just $10,000 of revenue against a $2.98 million net loss for the six months ended June 30, 2026, with Q2 revenue of only $3,000, down from $7,000 a year earlier. The company reiterated substantial doubt about its ability to continue as a going concern, disclosing only $10,000 of cash on hand at June 30, 2026 against $2.0 million of current liabilities, including $1.33 million due on demand to related party DSS, Inc. Material weaknesses in disclosure controls and procedures from the FY2025 Form 10-K remained unresolved, and management concluded the company's disclosure controls were not effective as of quarter end. DSS, Inc.
Key figures
- Eps
- -$0.03 basic and diluted for the six months ended June 30, 2026 (Q2 2026: -$0.01)
- Revenue
- $10,000 for the six months ended June 30, 2026 (Q2 2026: $3,000)
- Net Income
- -$2,983,000 for the six months ended June 30, 2026 (vs -$15,631,000 in the prior-year period, which included a $12,942,000 change in fair value of a related-party note)
- Revenue Yoy
- Six-month revenue up 43% ($10,000 vs $7,000); Q2 revenue down 57% ($3,000 vs $7,000)
- Cash Position
- $10,000 at June 30, 2026
- Shares Outstanding
- 107821231
- Total liabilities
- 2733000
- Stockholders equity
- 14012000
- Rnd expense six months
- 123000
- Due to related party dss
- 1330000
- Stock based compensation six months
- 1440000
- Shares issued for stock comp jan 2026
- 3200000
- Net cash provided by operating six months
- 6000
Price after filing
Close on the filing date to close N calendar days later (from $0.45). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.